Any current/future capex/capital investment/strategic investment?

For the first 9 months of FY24, capital expenditure was INR 287 crores, with nearly 60% allocated to expanding capacity. Future plans include adding 1,700 beds by 2027 through a mix of brownfield (60%) and greenfield projects. Brownfield expansions are ongoing in Kerala (e.g., Medcity) and Karnataka. Greenfield projects include a 460-bed hospital in Trivandrum and a 250-bed hospital in Kasargod, Kerala. Plans also involve inorganic expansion opportunities in neighboring geographies and states like Maharashtra and Uttar Pradesh. Expansion strategy focuses on both large (500-bed) hospitals in me

Future growth expectations in sales/revenue/volumes?

India business expects robust growth, with revenue increasing 23% YoY to Rs 949 crores in Q3 FY24, driven by capacity expansion adding 750+ beds this year. The healthcare market in India is projected to grow at 22% CAGR, reaching USD 638 billion by 2025. Plans to add approximately 1,700 beds by FY27 to reach over 6,600 total bed capacity. Mature hospitals show strong revenue growth (16% increase YoY) and improved margins. New-age hospitals like Whitefield in Bangalore expected to ramp up quickly, achieving utilization of 60-70% and breakeven within 12 months. ARPOB growth is sustainable at 8-9

Current/ Expected Orderbook/ Pending Orders?

There is a pipeline of approximately 1,700 beds planned for expansion. Of these, around 450 beds are part of a greenfield project at Aster Capital, Trivandrum. Another greenfield project is underway in Kasargod, Kerala, with approximately 254 beds. The majority of the remaining pipeline consists of brownfield expansions or O&M (Operation & Management) projects. Operational beds awaiting activation—around 250 to 300—are ready with equipment and furnishings in three locations: Guntur (Andhra Pradesh), Aster Whitefield Hospital expansion (phase two with 150 beds pending), and Aster G Madegowda Ho

Aster DM QualityQ3 FY24Healthcare Services

Aster DM Quality Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹709P/E: 183.4Market Cap: ₹66.2K CrSector: Healthcare Services

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

India business expects robust growth, with revenue increasing 23% YoY to Rs 949 crores in Q3 FY24, driven by capacity expansion adding 750+ beds this year.
The healthcare market in India is projected to grow at 22% CAGR, reaching USD 638 billion by 2025.
Plans to add approximately 1,700 beds by FY27 to reach over 6,600 total bed capacity.
Mature hospitals show strong revenue growth (16% increase YoY) and improved margins.
New-age hospitals like Whitefield in Bangalore expected to ramp up quickly, achieving utilization of 60-70% and breakeven within 12 months.
ARPOB growth is sustainable at 8-9%, with current 9M period reflecting over 12% growth.
The lab business expected to break even by Q4 FY24; pharmacy to break even in 1-2 years.
Overall EBITDA margin expected to improve by 300-400 bps over next 2-3 years.

Margin guidance

- India segment expects significant margin expansion with 300-400 basis points increase over the next 2-3 years driven by capacity expansions, higher occupancy, and cost optimization. - Consolidated EBITDA growth guided beyond current levels, with India hospitals and clinics segment targeting over 20% EBITDA margins sustainably. - New hospital expansions (including 1,700 beds in next 2-3 years) projected to drive revenue and profitability growth with limited EBITDA drag. - ARPOB (Average Revenue Per Occupied Bed) growth of 8-9% is sustainable, supporting revenue increases. - GCC operations show steady 14-15% revenue growth and improved operating EBITDA margins (~15% in Q3 FY24 vs 13.8% last year). - Overall consolidated EBITDA grew 28% YoY to INR 583 crore in Q3 FY24; adjusted PAT increased 53% YoY. - Plans include continued revenue assurance, operational efficiency, and selective inorganic growth with potential PE partnership to accelerate value creation. - Dividend pay-out expected at 70-80%, with balance to support growth or debt reduction. Overall outlook indicates healthy double-digit earnings and operating profit growth in the medium term.

See what Aster DM Quality management said on margin guidance — free account, 30 seconds.

Fundraise plans

- The company is exploring strategic partnerships, including potential private equity (PE) investment, to support inorganic growth and new initiatives in India. (Page 16) - Organic growth plans for India are largely self-funded through cash generation from existing businesses, with India generating sufficient cash for its organic expansion. (Page 16) - PE partnership is intended to be an add-on to accelerate inorganic growth and other strategic initiatives rather than replace organic funding. (Page 16) - No explicit mention of new debt fundraising for expansion; net debt position updated but no new debt plans disclosed. (Page 10, 9) - Dividend distribution of 70%-80% of upfront consideration from GCC sale planned, with the balance funds possibly used for inorganic expansion or debt reduction. (Page 16, 5) In summary, while active fundraising via PE is being evaluated for inorganic growth acceleration, organic growth remains primarily self-funded, with no explicit new debt or equity issuance announced as of now.

Order book

There is a pipeline of approximately 1,700 beds planned for expansion.
Of these, around 450 beds are part of a greenfield project at Aster Capital, Trivandrum.
Another greenfield project is underway in Kasargod, Kerala, with approximately 254 beds.
The majority of the remaining pipeline consists of brownfield expansions or O&M (Operation & Management) projects.
Operational beds awaiting activation—around 250 to 300—are ready with equipment and furnishings in three locations: Guntur (Andhra Pradesh), Aster Whitefield Hospital expansion (phase two with 150 beds pending), and Aster G Madegowda Hospital.
Capacity expansion focuses both on asset-light O&M models and greenfield projects, aiming to optimize operational efficiency and financial viability.

See what Aster DM Quality management said on order book — free account, 30 seconds.

Capex plans

For the first 9 months of FY24, capital expenditure was INR 287 crores, with nearly 60% allocated to expanding capacity.
Future plans include adding 1,700 beds by 2027 through a mix of brownfield (60%) and greenfield projects.
Brownfield expansions are ongoing in Kerala (e.g., Medcity) and Karnataka.
Greenfield projects include a 460-bed hospital in Trivandrum and a 250-bed hospital in Kasargod, Kerala.
Plans also involve inorganic expansion opportunities in neighboring geographies and states like Maharashtra and Uttar Pradesh.
Expansion strategy focuses on both large (500-bed) hospitals in metros and mid-sized (200-300 bed) hospitals in tier 2 and tier 3 cities.
Labs and pharmacies network is being optimized to break even and scale sustainably.
There's potential strategic partnership/PE fund deployment aimed largely at inorganic growth and new initiatives, supplementing organic plans.
Cost-saving initiatives and margin improvements are ongoing alongside expansion to ensure financial viability.

Track Aster DM Quality — get its next earnings analysis in your feed

How does Aster DM Quality rank vs peers in Healthcare Services?

Pro feature

ThisAster DM Quality

See where Aster DM Quality sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Aster DM Quality rank in Healthcare Services?

Compare Aster DM Quality against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Aster DM Quality's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →